Cadrenal Therapeutics Inc — Cash Flow (NASDAQ:CVKD)

Financials

Cash from operating activities -60-3.53 M-7.36 M-12.6 M -12.6 M Cash from investing activities —-3 254-6 537-5 104 -5 104 Cash from financing activities —11.9 M8.98 M6.6 M 6.6 M Free cash flow -60-3.53 M-7.36 M-12.61 M -12.61 M

뉴스

Cadrenal schedules FDA meeting for HIT drug CAD-1005

카데레날 테라퓨틱스, 2상 임상 결과 발표 후 주가 급등

Cadrenal Therapeutics stock surges on Phase 2 trial results

카드레날, HIT 임상시험서 CAD-1005 혈전 감소 효과 보여

Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial

카드레날, 혈액 질환 치료제 ’12-LOX 억제제’ 잠재력 강조

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board

Cadrenal Therapeutics, Inc.

캐드레날 테라퓨틱스 CFO Szot, 주식 1496달러 상당 매도